<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04941209</url>
  </required_header>
  <id_info>
    <org_study_id>L42AI-20210003</org_study_id>
    <nct_id>NCT04941209</nct_id>
  </id_info>
  <brief_title>imPulse™ Una Infrasound-to-ultrasound E-stethoscope</brief_title>
  <official_title>imPulse™ Una Infrasound-to-ultrasound E-stethoscope 2-minute to Result COVID-19 Self-directed &amp; Point-of-care Screening Test</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Level 42 AI, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Asian Institute of Public Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut de Recherche en Santé de Surveillance Epidemiologique et de Formation (IRESSEF)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laboratoire de la foundation Gombes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Level 42 AI, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study generates robust, uniform clinical data across emerging COVID-19 strains to train&#xD;
      ML/AI algorithms of the Sponsor's imPulse™ Una infrasound-to-ultrasound e-stethoscope for&#xD;
      digital diagnostic feature synthesis of asymptomatic and symptomatic COVID-19 digital&#xD;
      biosignatures for rapid and accurate adult and child mass screening.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For the next few years or more, the planet probably won't have enough vaccine for everyone.&#xD;
      Even as countries with large COVID-19 vaccination programs start pushing to resume travel and&#xD;
      trade:&#xD;
&#xD;
      We will not know who is vaccinated and who is not . We will not know who is an (a)symptomatic&#xD;
      COVID-19 carrier and who is not.&#xD;
&#xD;
      Because of this, the global community will remain in various stages of masking, social&#xD;
      distancing, lock-down, and limited congregation because of cyclical COVID-19 spikes and&#xD;
      people will continue to feel unsafe and afraid as novel COVID-19 variants appear and&#xD;
      disappear.&#xD;
&#xD;
      This large-scale, multi-site, multi-national study is informed by a completed pilot study at&#xD;
      Johns Hopkins- NCT04556149. This study is designed to validate the ability of the imPulse™&#xD;
      Una infrasound-to-ultrasound e-stethoscope to rapidly and accurately screen outpatients with&#xD;
      and without confirmed COVID-19 with sensitivity, specificity, positive and negative&#xD;
      predictive value matching (PPA &gt;95%) for early, accurate, and rapid, self-directed and&#xD;
      point-of-care diagnosis of COVID-19 in areas still lagging in access to vaccines.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 11, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Digital vibroacoustic biomarker diagnostic performance characteristics</measure>
    <time_frame>Enrollment through to study completion (min 48hrs through to 3 months)</time_frame>
    <description>Sensitivity, specificity, positive and negative predictive values - of the imPulse™ Una device for point-of-care diagnosis of COVID-19.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>imPulse™ Una infrasound-to-ultrasound e-stethoscope device safety</measure>
    <time_frame>Enrollment through to study completion (min 48hrs through to 3 months)</time_frame>
    <description>Device safety</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Covid19</condition>
  <condition>COVID-19 Pneumonia</condition>
  <condition>COVID-19 Respiratory Infection</condition>
  <condition>COVID-19 Acute Respiratory Distress Syndrome</condition>
  <condition>Mass Screening</condition>
  <condition>Corona Virus Infection</condition>
  <condition>Vaccine Virus Shedding</condition>
  <arm_group>
    <arm_group_label>Case</arm_group_label>
    <description>Inpatients/Outpatients with confirmed COVID-19 with and without pulmonary symptoms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matched-Control</arm_group_label>
    <description>Outpatients without COVID-19 without known non-pulmonary diagnoses or symptoms.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>imPulse™ Una infrasound-to-ultrasound e-stethoscope</intervention_name>
    <description>The imPulse™ System is an every/anywhere-point-of-care cardiopulmonary functional state assessment platform designed to capture normal and abnormal, audible and inaudible cardiopulmonary sounds, rhythms and patterns, via a real-time, intelligent, full-spectrum phonocardiogram obtained from direct to skin coupling or through a layer of clothing.</description>
    <arm_group_label>Case</arm_group_label>
    <arm_group_label>Matched-Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>(PPA &gt;95%) FDA EUA RT-PCR</intervention_name>
    <description>Real-time RT-PCR that detects amplified SARS-CoV-2 genome in sputum, nasopharyngeal or oropharyngeal swabs, bronchoalveolar lavage fluid, nasal or nasopharyngeal aspirate, and lower respiratory tract aspirates.</description>
    <arm_group_label>Case</arm_group_label>
    <arm_group_label>Matched-Control</arm_group_label>
    <other_name>RT-PCR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>HR-CT-scan</intervention_name>
    <description>High-resolution computer tomography, or CT/CAT, is an X-ray scan that produces images of the chest and is used as a confirmatory test in symptomatic patients that have a negative PCR test.</description>
    <arm_group_label>Case</arm_group_label>
    <other_name>CT</other_name>
    <other_name>CAT</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women/girls and men/boys meeting enrollment criteria will be recruited from among&#xD;
        hospitalized inpatients and outpatients with asymptomatic and symptomatic COVID-19&#xD;
        infection. One outpatient control without lung disease or pulmonary symptoms will be&#xD;
        selected for each enrolled case.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able to understand and willingness to comply with study procedures&#xD;
&#xD;
          -  Inpatient Cases - hospitalized patients with positive COVID-19 PCR test, collected&#xD;
             from a respiratory sample within the last 7 days, AND pulmonary symptoms within 72&#xD;
             hours of enrollment&#xD;
&#xD;
          -  Outpatient Cases - participant being screened for COVID-19 with positive COVID-19 PCR&#xD;
             test respiratory sample Controls - Outpatients with negative COVID-19 PCR test&#xD;
             respiratory sample and no pulmonary diagnosis or symptoms Cases or Control not able to&#xD;
             sit or stand will be allowed to participate in just the parts of the staircase exam&#xD;
             they're capable of doing.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Assisted ventilation, including high flow nasal cannula, or ventilator support&#xD;
&#xD;
          -  Unable to comply with study procedures, defined at investigator's discretion&#xD;
&#xD;
          -  Participants with any visible skin infections or open wounds in areas where the&#xD;
             imPulse™ Una device would be applied&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Shasha Jumbe, PhD</last_name>
    <phone>+16505156112</phone>
    <email>shasha@level42.ai</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mike Morimoto, PhD</last_name>
    <phone>+18058907553</phone>
    <email>mike@level42.ai</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Laboratoire de la foundation Gombes</name>
      <address>
        <city>Pointe Noire</city>
        <state>Kouilou</state>
        <country>Congo, The Democratic Republic of the</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hugues Loemba, MD</last_name>
      <phone>+ 1-613-564-3950</phone>
      <phone_ext>475</phone_ext>
      <email>hloemba@rogers.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asian Institute of Public Health</name>
      <address>
        <city>Bhubaneswar</city>
        <state>Odisha</state>
        <zip>751002</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karunakar Panda</last_name>
      <phone>(+91-94370-94230</phone>
      <email>kkpanda@aiph.ac.in</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute for Health Research, Epidemiological Surveillance and Training ( IRESSEF)</name>
      <address>
        <city>Dakar</city>
        <state>Almadies</state>
        <country>Senegal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daouda M Gueye, MD</last_name>
      <phone>+221338592596</phone>
      <email>daoudamalick.gueye@iressef.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Congo, The Democratic Republic of the</country>
    <country>India</country>
    <country>Senegal</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.gov/ct2/show/study/NCT04556149?term=infrasound&amp;draw=2</url>
    <description>SARS-CoV-2/COVID-19 Study of the Audible and Inaudible Vibroacoustic E-stethoscope - imPulse™ Una</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 20, 2021</study_first_submitted>
  <study_first_submitted_qc>June 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2021</study_first_posted>
  <last_update_submitted>June 20, 2021</last_update_submitted>
  <last_update_submitted_qc>June 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>infrasound</keyword>
  <keyword>ultrasound</keyword>
  <keyword>vibroacoustics</keyword>
  <keyword>vibrome</keyword>
  <keyword>digital-biosignature</keyword>
  <keyword>e-stethoscope</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

